Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 105420, 9 pages
http://dx.doi.org/10.1155/2014/105420
Research Article

The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human Neutrophils In Vitro

1Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria, P.O. Box 2034, Pretoria 0001, South Africa
2Tshwane Academic Division of the National Health Laboratory Service, Pretoria 0001, South Africa
3Division of Pulmonology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg 2193, South Africa

Received 8 November 2013; Revised 15 January 2014; Accepted 29 January 2014; Published 6 March 2014

Academic Editor: Giuseppe Valacchi

Copyright © 2014 Ronald Anderson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Cazzola, C. P. Page, P. Rogliani, and M. G. Matera, “β-agonist therapy in lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 7, pp. 690–696, 2013. View at Google Scholar
  2. M. R. Sears, “The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?” Thorax, vol. 68, no. 2, pp. 195–198, 2013. View at Publisher · View at Google Scholar
  3. M. Johnson, “Effects of β2-agonists on resident and infiltrating inflammatory cells,” Journal of Allergy and Clinical Immunology, vol. 110, no. 6, pp. S282–S290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. C. H. Serezani, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden, “Cyclic AMP: master regulator of innate immune cell function,” American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 2, pp. 127–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. J. Theron, H. C. Steel, G. R. Tintinger, C. Feldman, and R. Anderson, “Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?” Journal of Drug Design, Development and Therapy, vol. 2013, no. 7, Article ID S50995, pp. 1387–11398, 2013. View at Publisher · View at Google Scholar
  6. M. A. Matthay, R. G. Brower, S. Carson et al., “Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 5, pp. 561–568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. F. G. Smith, G. D. Perkins, S. Gates et al., “Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial,” The Lancet, vol. 379, no. 9812, pp. 229–235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Barnes, “Effect of β-agonists on inflammatory cells,” Journal of Allergy and Clinical Immunology, vol. 104, no. 2, part 2, pp. S10–S17, 1999. View at Google Scholar · View at Scopus
  9. S. M. Ray, J. C. McMillen, S. A. Treadway, R. S. Helmer, and A. S. Franks, “Indacaterol: a novel long-acting β(2)-agonist,” Pharmacotherapy, vol. 32, no. 5, pp. 456–474, 2012. View at Publisher · View at Google Scholar
  10. J. Han, L. Dai, and N. Zhong, “Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials,” BMC Pulmonary Medicine, vol. 13, article 26, 2013. View at Google Scholar
  11. C. De Coupade, R. W. Gear, P. F. Dazin, H. Y. Sroussi, P. G. Green, and J. D. Levine, “β2-adrenergic receptor regulation of human neutrophil function is sexually dimorphic,” British Journal of Pharmacology, vol. 143, no. 8, pp. 1033–1041, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Hoenderkos and A. Condliffe, “The neutrophil in chronic obstructive pulmonary disease,” American Journal of Respiratory Cell and Molecular Biology, vol. 48, no. 5, pp. 531–539, 2013. View at Google Scholar
  13. P. J. Barnes, “New molecular targets for the treatment of neutrophilic diseases,” Journal of Allergy and Clinical Immunology, vol. 119, no. 5, pp. 1055–1062, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. L. Tannheimer, C. D. Wright, and M. Salmon, “Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts,” Respiratory Research, vol. 13, article 28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A.-M. Scola, M. Loxham, S. J. Charlton, and P. T. Peachell, “The long-acting β-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells,” British Journal of Pharmacology, vol. 158, no. 1, pp. 267–276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C. M. Gravett, A. J. Theron, H. C. Steel et al., “Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils,” The European Respiratory Journal, vol. 36, no. 6, pp. 1417–1424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Grynkiewicz, M. Poenie, and R. Y. Tsien, “A new generation of Ca2+ indicators with greatly improved fluorescence properties,” The Journal of Biological Chemistry, vol. 260, no. 6, pp. 3440–3450, 1985. View at Google Scholar · View at Scopus
  18. R. Anderson and A. G. Mahomed, “Calcium efflux and influx in f-met-leu-phe (fMLP)-activated human neutrophils are chronologically distinct events,” Clinical and Experimental Immunology, vol. 110, no. 1, pp. 132–138, 1997. View at Google Scholar · View at Scopus
  19. H. C. Steel and R. Anderson, “Dissociation of the PAF-receptor from NADPH oxidase and adenylate cyclase in human neutrophils results in accelerated influx and delayed clearance of cytosolic calcium,” British Journal of Pharmacology, vol. 136, no. 1, pp. 81–89, 2002. View at Google Scholar · View at Scopus
  20. M. Cazzola and M. G. Matera, “Emerging inhaled bronchodilators: an update,” European Respiratory Journal, vol. 34, no. 3, pp. 757–769, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. W. Mak and M. M. W. Chan-Yeung, “Reactive oxidant species in asthma,” Current Opinion in Pulmonary Medicine, vol. 12, no. 1, pp. 7–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. K.-Y. Lee, S.-C. Ho, H.-C. Lin et al., “Neutrophil-derived elastase induces TGF-β1 secretion in human airway smooth muscle via NF-κB pathway,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 4, pp. 407–414, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. Q. Li, X. Zhou, H. Yu, X. Nie, and X. Xu, “Roles of ROS/TACE in neutrophil elastase-induced mucus hypersecretion in NCI-H292 airway epithelial cells,” European Cytokine Network, vol. 21, no. 3, pp. 177–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Ohnishi, N. Miyahara, and E. W. Gelfand, “The role of leukotriene B4 in allergic diseases,” Allergology International, vol. 57, no. 4, pp. 291–298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. I. T. Lee and C. M. Yang, “Role of NADH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases,” Biochemical Pharmacology, vol. 84, no. 5, pp. 581–590, 2012. View at Publisher · View at Google Scholar
  26. A. Gaggar, A. Hector, P. E. Bratcher, M. A. Mall, M. Griese, and D. Hartl, “Series “matrix metalloproteinases in lung health and disease”: the role of matrix metalloproteinases in cystic fibrosis lung disease,” The European Respiratory Journal, vol. 38, no. 3, pp. 721–727, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. R. A. Sandhaus and G. Torino, “Neutrophil elastase-mediated lung disease,” COPD, vol. 10, supplement 1, pp. 60–63, 2013. View at Publisher · View at Google Scholar
  28. R. Anderson, A. Goolam Mahomed, A. J. Theron, G. Ramafi, and C. Feldman, “Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils,” British Journal of Pharmacology, vol. 124, no. 3, pp. 547–555, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Brunskole Hummel, M. T. Reinartz, S. Kälble et al., “Dissociations in the effects of β2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity,” PLoS ONE, vol. 8, no. 5, Article ID e64556, 2013. View at Google Scholar
  30. M. Bosmann, J. J. Grailer, K. Zhu et al., “Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury,” The FASEB Journal, vol. 26, no. 5, pp. 2137–2144, 2012. View at Google Scholar
  31. J. L. Black, B. G. G. Oliver, and M. Roth, “Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β-agonists,” Chest, vol. 136, no. 4, pp. 1095–1100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. F. Chung, G. Caramori, and I. M. Adcock, “Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future,” European Journal of Clinical Pharmacology, vol. 65, no. 9, pp. 853–871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Ridolo, M. Montagni, E. Olivieri, G. G. Riario-Sforza, and C. Incorvaia, “Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 2013, no. 8, pp. 425–432, 2013. View at Publisher · View at Google Scholar
  34. A. Rossi and G. Polese, “Indacaterol: a comprehensive review,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 2013, no. 8, pp. 353–363, 2013. View at Publisher · View at Google Scholar
  35. S. Khindri, R. Sabo, S. Harris, R. Woessner, S. Jennings, and A. F. Drollmann, “Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study,” BMC Pulmonary Medicine, vol. 11, article 31, 2011. View at Publisher · View at Google Scholar · View at Scopus